Phase 1 and phase 2a first-in-human study of DRP-104 a glutamine antagonist in adult patients with advanced solid tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Solid Tumors
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Diagnosis of advanced or recurrent, histologically or cytologically confirmed, solid malignancy that is either metastatic or unresectable. 2. Patients must have measurable disease.

You may not be eligible for this study if the following are true:

  • 1. Patients with primary central nervous system tumors and hepatocellular carcinoma. 2. Patients with progressive or symptomatic brain metastases. 3. Leptomeningeal disease

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.